Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.

Expert opinion on drug metabolism & toxicology - 1 Jul 2012

Chan Sze Wa, Hu Miao, Tomlinson Brian

Abstract excerpt

INTRODUCTION: β-Blockers have an important therapeutic role throughout the cardiovascular continuum. However, there is considerable variation in response to these drugs, which may be related to genetic influences on their pharmacokinetics and pharmacodynamic effects. AREAS COVERED: This review focuses on genetic variations in the drug metabolizing enzymes which influence the pharmacokinetics and potentially the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Heart Failure

Share to Hypertension

Share to Pharmacogenetics

Share to Receptors, Adrenergic, beta

Share to Signal Transduction

Source

Identifiers

PMID: 22621216
DOI: 10.1517/17425255.2012.685157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.PMID 22621216Read ↗

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Genetic variation, β-blockers, and perioperative myocardial infarction.Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.Semantic proximity Read ↗

β-Adrenergic Receptor Polymorphisms: Cardiovascular Disease Associations and PharmacogeneticsSemantic proximity Read ↗

Genetic polymorphisms influencing antihypertensive drug responsesSemantic proximity Read ↗

Pharmacogenetics of Beta-1- and Beta-2-Adrenergic ReceptorsSemantic proximity Read ↗

[Adrenergic receptor polymorphisms in heart failure: what can genetics explain?].Semantic proximity Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.Semantic proximity Read ↗

Pharmacogenomics of β-adrenergic receptor physiology and response to β-blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.